Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

2.

Identification of MS-specific serum miRNAs in an international multicenter study.

Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 20;5(5):e491. doi: 10.1212/NXI.0000000000000491. eCollection 2018 Sep.

3.

A probiotic modulates the microbiome and immunity in multiple sclerosis.

Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, Kivisäkk P, Pierre IV, Hrishikesh L, Gandhi R, Cook S, Glanz B, Stankiewicz J, Weiner HL.

Ann Neurol. 2018 Jun;83(6):1147-1161. doi: 10.1002/ana.25244. Epub 2018 Jun 8.

4.

Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.

Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, Paul A, Diaz-Cruz C, Gholipour T, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Berry JD, Gandhi R.

Muscle Nerve. 2018 Aug;58(2):261-269. doi: 10.1002/mus.26106. Epub 2018 Mar 25.

5.

Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.

Bove R, Healy BC, Musallam A, Soltany P, Diaz-Cruz C, Sattarnezhad N, Glanz BI, Kivisäkk P, Miller KK, Chitnis T.

Mult Scler. 2019 Mar;25(3):344-351. doi: 10.1177/1352458517750768. Epub 2018 Jan 11.

PMID:
29320952
6.

Investigation of probiotics in multiple sclerosis.

Tankou SK, Regev K, Healy BC, Cox LM, Tjon E, Kivisakk P, Vanande IP, Cook S, Gandhi R, Glanz B, Stankiewicz J, Weiner HL.

Mult Scler. 2018 Jan;24(1):58-63. doi: 10.1177/1352458517737390. Erratum in: Mult Scler. 2019 Jan;25(1):176.

PMID:
29307299
7.

Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis.

Hu D, Notarbartolo S, Croonenborghs T, Patel B, Cialic R, Yang TH, Aschenbrenner D, Andersson KM, Gattorno M, Pham M, Kivisakk P, Pierre IV, Lee Y, Kiani K, Bokarewa M, Tjon E, Pochet N, Sallusto F, Kuchroo VK, Weiner HL.

Nat Commun. 2017 Nov 17;8(1):1600. doi: 10.1038/s41467-017-01571-8.

8.

Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.

Mazzola MA, Raheja R, Regev K, Beynon V, von Glehn F, Paul A, Pierre I, Kivisakk P, Weiner HL, Gandhi R.

Mult Scler. 2019 Jan;25(1):63-71. doi: 10.1177/1352458517740213. Epub 2017 Nov 6.

PMID:
29106333
9.

Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS.

Rothhammer V, Borucki DM, Garcia Sanchez MI, Mazzola MA, Hemond CC, Regev K, Paul A, Kivisäkk P, Bakshi R, Izquierdo G, Weiner HL, Quintana FJ.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e359. doi: 10.1212/NXI.0000000000000359. eCollection 2017 Jul.

10.

Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.

Regev K, Healy BC, Khalid F, Paul A, Chu R, Tauhid S, Tummala S, Diaz-Cruz C, Raheja R, Mazzola MA, von Glehn F, Kivisakk P, Dupuy SL, Kim G, Chitnis T, Weiner HL, Gandhi R, Bakshi R.

JAMA Neurol. 2017 Mar 1;74(3):275-285. doi: 10.1001/jamaneurol.2016.5197.

11.

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis.

Regev K, Paul A, Healy B, von Glenn F, Diaz-Cruz C, Gholipour T, Mazzola MA, Raheja R, Nejad P, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Gandhi R.

Neurol Neuroimmunol Neuroinflamm. 2016 Aug 23;3(5):e267. doi: 10.1212/NXI.0000000000000267. eCollection 2016 Oct. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2016 Oct 07;3(6):e296.

12.

Alterations of the human gut microbiome in multiple sclerosis.

Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L, Weiner HL.

Nat Commun. 2016 Jun 28;7:12015. doi: 10.1038/ncomms12015.

13.

Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis.

Bakshi R, Yeste A, Patel B, Tauhid S, Tummala S, Rahbari R, Chu R, Regev K, Kivisäkk P, Weiner HL, Quintana FJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e200. doi: 10.1212/NXI.0000000000000200. eCollection 2016 Apr.

14.

Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation.

Mazzola MA, Raheja R, Murugaiyan G, Rajabi H, Kumar D, Pertel T, Regev K, Griffin R, Aly L, Kivisakk P, Nejad P, Patel B, Gwanyalla N, Hei H, Glanz B, Chitnis T, Weiner HL, Gandhi R.

J Neuroinflammation. 2015 Dec 30;12:245. doi: 10.1186/s12974-015-0460-z.

15.

Effect of vitamin D on MS activity by disease-modifying therapy class.

Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz B, Chitnis T.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 29;2(6):e167. doi: 10.1212/NXI.0000000000000167. eCollection 2015 Dec.

16.

Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.

Mayo L, Trauger SA, Blain M, Nadeau M, Patel B, Alvarez JI, Mascanfroni ID, Yeste A, Kivisäkk P, Kallas K, Ellezam B, Bakshi R, Prat A, Antel JP, Weiner HL, Quintana FJ.

Nat Med. 2014 Oct;20(10):1147-56. doi: 10.1038/nm.3681. Epub 2014 Sep 14.

17.

Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.

Kivisäkk P, Francois K, Mbianda J, Gandhi R, Weiner HL, Khoury SJ.

PLoS One. 2014 Jul 30;9(7):e103716. doi: 10.1371/journal.pone.0103716. eCollection 2014.

18.

Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis.

Malik MT, Healy BC, Benson LA, Kivisakk P, Musallam A, Weiner HL, Chitnis T.

Neurology. 2014 Jun 17;82(24):2173-9. doi: 10.1212/WNL.0000000000000524. Epub 2014 May 21.

19.

Increased leptin and A-FABP levels in relapsing and progressive forms of MS.

Messina S, Vargas-Lowy D, Musallam A, Healy BC, Kivisakk P, Gandhi R, Bove R, Gholipour T, Khoury S, Weiner HL, Chitnis T.

BMC Neurol. 2013 Nov 11;13:172. doi: 10.1186/1471-2377-13-172.

20.

Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.

Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, Khoury SJ.

Mult Scler. 2014 Apr;20(4):438-44. doi: 10.1177/1352458513503052. Epub 2013 Sep 4.

PMID:
24005026
21.

Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.

Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain MS, Nejad P, Patel B, Hei H, Khoury S, Quintana F, Kivisakk P, Chitnis T, Weiner HL.

Ann Neurol. 2013 Jun;73(6):729-40. doi: 10.1002/ana.23880. Epub 2013 Jul 8.

PMID:
23494648
22.

Increased Th17 response to myelin peptides in pediatric MS.

Vargas-Lowy D, Kivisäkk P, Gandhi R, Raddassi K, Soltany P, Gorman MP, Khoury SJ, Chitnis T.

Clin Immunol. 2013 Mar;146(3):176-84. doi: 10.1016/j.clim.2012.12.008. Epub 2012 Dec 28.

PMID:
23352968
23.

Reversible neural stem cell niche dysfunction in a model of multiple sclerosis.

Rasmussen S, Imitola J, Ayuso-Sacido A, Wang Y, Starossom SC, Kivisäkk P, Zhu B, Meyer M, Bronson RT, Garcia-Verdugo JM, Khoury SJ.

Ann Neurol. 2011 May;69(5):878-91. doi: 10.1002/ana.22299. Epub 2011 Mar 9.

24.

A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.

Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S.

Arch Neurol. 2010 Sep;67(9):1055-61. doi: 10.1001/archneurol.2010.222.

25.

Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells.

Ilan Y, Zigmond E, Lalazar G, Dembinsky A, Ben Ya'acov A, Hemed N, Kasis I, Axelrod E, Zolotarov L, Klein A, El Haj M, Gandhi R, Baecher-Allan C, Wu H, Murugaiyan G, Kivisakk P, Farez MF, Quintana FJ, Khoury SJ, Weiner HL.

J Clin Immunol. 2010 Jan;30(1):167-77. doi: 10.1007/s10875-009-9323-7. Epub 2009 Sep 16.

26.

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

Kivisäkk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, Khoury SJ.

Neurology. 2009 Jun 2;72(22):1922-30. doi: 10.1212/WNL.0b013e3181a8266f.

27.

Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury.

Fox RJ, Kivisakk P, Fisher E, Tucky B, Lee JC, Rudick RA, Ransohoff RM.

Mult Scler. 2008 Sep;14(8):1036-43. doi: 10.1177/1352458508092261. Epub 2008 Aug 13.

PMID:
18701575
28.

Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis.

Elyaman W, Kivisäkk P, Reddy J, Chitnis T, Raddassi K, Imitola J, Bradshaw E, Kuchroo VK, Yagita H, Sayegh MH, Khoury SJ.

Am J Pathol. 2008 Aug;173(2):411-22. doi: 10.2353/ajpath.2008.080142. Epub 2008 Jun 26.

29.

Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis.

Kivisäkk P, Imitola J, Rasmussen S, Elyaman W, Zhu B, Ransohoff RM, Khoury SJ.

Ann Neurol. 2009 Apr;65(4):457-69. doi: 10.1002/ana.21379.

30.

JAGGED1 and delta1 differentially regulate the outcome of experimental autoimmune encephalomyelitis.

Elyaman W, Bradshaw EM, Wang Y, Oukka M, Kivisäkk P, Chiba S, Yagita H, Khoury SJ.

J Immunol. 2007 Nov 1;179(9):5990-8.

31.
32.

Chemokine receptors as biomarkers in multiple sclerosis.

Fox RJ, Kivisäkk P, Lee JC, Tucky B, Lucchinetti C, Rudick RA, Ransohoff RM.

Dis Markers. 2006;22(4):227-33.

33.
34.

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, Hofbauer M, Farina C, Derfuss T, Hartle C, Newcombe J, Hohlfeld R, Meinl E.

Brain. 2006 Jan;129(Pt 1):200-11. Epub 2005 Nov 9.

PMID:
16280350
35.

Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis.

Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivisäkk P, Tucky B, Kidd G, Kingsbury GA, Chang A, Fox RJ, Mack M, Sniderman MB, Ravid R, Staugaitis SM, Stins MF, Ransohoff RM.

Brain. 2006 Jan;129(Pt 1):212-23. Epub 2005 Oct 17.

PMID:
16230319
36.

Comparison of ventricular and lumbar cerebrospinal fluid T cells in non-inflammatory neurological disorder (NIND) patients.

Provencio JJ, Kivisäkk P, Tucky BH, Luciano MG, Ransohoff RM.

J Neuroimmunol. 2005 Jun;163(1-2):179-84. Epub 2005 Apr 22.

PMID:
15885320
37.

A role for CCR4 in development of mature circulating cutaneous T helper memory cell populations.

Baekkevold ES, Wurbel MA, Kivisäkk P, Wain CM, Power CA, Haraldsen G, Campbell JJ.

J Exp Med. 2005 Apr 4;201(7):1045-51. Epub 2005 Mar 28.

38.

CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer.

Callahan MK, Williams KA, Kivisäkk P, Pearce D, Stins MF, Ransohoff RM.

J Neuroimmunol. 2004 Aug;153(1-2):150-7.

PMID:
15265673
39.

Expression of CCR7 in multiple sclerosis: implications for CNS immunity.

Kivisäkk P, Mahad DJ, Callahan MK, Sikora K, Trebst C, Tucky B, Wujek J, Ravid R, Staugaitis SM, Lassmann H, Ransohoff RM.

Ann Neurol. 2004 May;55(5):627-38.

PMID:
15122702
40.

Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions.

Mahad DJ, Trebst C, Kivisäkk P, Staugaitis SM, Tucky B, Wei T, Lucchinetti CF, Lassmann H, Ransohoff RM.

J Neuropathol Exp Neurol. 2004 Mar;63(3):262-73.

PMID:
15055450
41.

Preliminary observations on CC chemokine receptor expression by mononuclear phagocytes in multiple sclerosis lesions: effect of lesion heterogeneity.

Mahad D, Trebst C, Staugaitis SM, Kivisäkk P, Tucky B, Wei T, Horuk R, Ransohoff RM.

Ernst Schering Res Found Workshop. 2004;(45):59-68. No abstract available.

PMID:
14699794
42.

Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells.

Kivisäkk P, Cotleur AC, Lee JC, Rudick RA, Ransohoff RM.

J Neuroimmunol. 2003 Aug;141(1-2):150-4.

PMID:
12965266
43.

Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables.

Putheti P, Morris M, Stawiarz L, Teleshova N, Kivisäkk P, Pashenkov M, Kouwenhoven M, Wiberg MK, Bronge L, Huang YM, Söderström M, Hillert J, Link H.

Eur J Neurol. 2003 Sep;10(5):529-35.

PMID:
12940835
44.

Three or more routes for leukocyte migration into the central nervous system.

Ransohoff RM, Kivisäkk P, Kidd G.

Nat Rev Immunol. 2003 Jul;3(7):569-81. Review.

PMID:
12876559
45.

Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin.

Kivisäkk P, Mahad DJ, Callahan MK, Trebst C, Tucky B, Wei T, Wu L, Baekkevold ES, Lassmann H, Staugaitis SM, Campbell JJ, Ransohoff RM.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8389-94. Epub 2003 Jun 26.

46.

Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Kivisäkk P, Trebst C, Lee JC, Tucky BH, Rudick RA, Campbell JJ, Ransohoff RM.

J Neurovirol. 2003 Jun;9(3):291-9.

PMID:
12775413
47.

Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes.

Kivisäkk P, Liu Z, Trebst C, Tucky B, Wu L, Stine J, Mack M, Rudick RA, Campbell JJ, Ransohoff RM.

Methods. 2003 Apr;29(4):319-25.

PMID:
12725798
48.

CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages.

Trebst C, Staugaitis SM, Kivisäkk P, Mahad D, Cathcart MK, Tucky B, Wei T, Rani MR, Horuk R, Aldape KD, Pardo CA, Lucchinetti CF, Lassmann H, Ransohoff RM.

Am J Pathol. 2003 Feb;162(2):427-38.

49.

T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking.

Kivisäkk P, Trebst C, Liu Z, Tucky BH, Sørensen TL, Rudick RA, Mack M, Ransohoff RM.

Clin Exp Immunol. 2002 Sep;129(3):510-8.

50.

Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid.

Teleshova N, Pashenkov M, Huang YM, Söderström M, Kivisäkk P, Kostulas V, Haglund M, Link H.

J Neurol. 2002 Jun;249(6):723-9.

PMID:
12111306

Supplemental Content

Loading ...
Support Center